脉络通胶囊联合瑞舒伐他汀对冠心病经皮冠状动脉介入术后患者的临床疗效研究  

Clinical Effect of Mailuotong Capsule combined with Rosuvastatin on Coronary Heart Disease after Percutaneous Coronary Intervention

作　　者：王玉晓 栾献亭 王艳红 张锐 WANG Yu-xiao;LUAN Xian-ting;WANG Yan-hong;ZHANG Rui(Department of Cardiovascular Medicine,Second People’s Hospital of Pingdingshan City,Pingdingshan 467000,China)

机构地区：[1]平顶山市第二人民医院心血管内科,平顶山467000

出　　处：《中国合理用药探索》2022年第1期90-95,共6页Chinese Journal of Rational Drug Use

基　　金：“十二五”国家科技支撑计划资助项目(2011BAI11B02)。

摘　　要：目的:研究脉络通胶囊联合瑞舒伐他汀对冠心病经皮冠状动脉介入(PCI)术后患者的临床疗效。方法:本研究为前瞻性随机对照试验,选取2018年3月~2019年12月于本院行PCI术治疗的冠心病患者作为研究对象,通过优效性检验样本量计算确定样本量。结合文献资料预计所需样本量为54例/组,合计108例。考虑到10%的脱落情况,共纳入120例。将纳入患者按随机数字表法分为对照组和治疗组,各60例。有5例在临床调研期间失访,共有115例完成试验,其中对照组58例,治疗组57例。所有患者均给予常规治疗,对照组在常规治疗基础上给予瑞舒伐他汀钙片治疗,治疗组在对照组基础上联合脉络通胶囊治疗。治疗后评定两组临床疗效,检测两组治疗前和治疗后血清炎症因子[肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)、C反应蛋白(CRP)]及血脂[总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)]水平,并统计两组术后1年内主要心血管不良事件(MACE)发生率。结果:治疗组总有效率(91.23%)高于对照组(70.69%,P<0.05);治疗后,两组血清TNF-α、IL-6、CRP、TC、LDL-C、HDL-C水平优于治疗前,且治疗组优于对照组(P<0.05);治疗组MACE发生率(1.75%)低于对照组(13.79%,P<0.05)。结论:脉络通胶囊联合瑞舒伐他汀用于冠心病PCI术后治疗的效果较佳,可改善患者症状及心功能,降低血清炎症因子水平,有效调节血脂水平,减少MACE的发生。Objective:To study the clinical effect of Mailuotong capsule combined with rosuvastatin on coronary heart disease after percutaneous coronary intervention(PCI).Methods:This study was a prospective randomized controlled trial.Patients with coronary heart disease who underwent PCI in our hospital from March 2018 to December 2019 were selected as the research subjects,and the sample size was determined by the optimal efficiency test.Combined with the literatures,it was estimated that the required sample size was 54 cases/group,a total of 108 cases.Taking into account 10%of the samples falling off,a total of 120 cases were included.According to random number table method,the included patients were divided into the control group and the treatment group,with 60 cases in each group.Five cases were lost during the clinical investigation,and a total of 115 cases completed the trial,including 58 cases in the control group and 57 cases in the treatment group.All patients were given conventional treatment,the control group was treated with rosuvastatin calcium tablets on the basis of conventional treatment,and the treatment group was treated with Mailuotong capsule on the basis of the control group.The clinical effects of the two groups were evaluated after treatment.The levels of serum inflammatory factors[tumor necrosis factor-α(TNF-α),interleukin-6(IL-6),C reactive protein(CRP)]and blood lipids[total cholesterol(TC),low density lipoprotein cholesterol(LDL-C),high density lipoprotein cholesterol(HDL-C)]of the two groups were measured before and after treatment.The incidence of major adverse cardiovascular events(MACE)in the two groups within 1 year after operation was counted.Results:The total effective rate of the treatment group(91.23%)was higher than that of the control group(70.69%,P<0.05).After treatment,the levels of serum TNF-α,IL-6,CRP,TC,LDL-C and HDL-C in the treatment group were better than those in the control group(P<0.05).The incidence of MACE in the treatment group(1.75%)was lower than that in the control

关 键 词：脉络通胶囊 瑞舒伐他汀 冠心病 经皮冠状动脉介入 临床疗效 

分 类 号：R972[医药卫生—药品]